Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

GE Announces Completion of BioPharma Sale to Danaher, Receives $20 Billion Net Cash Proceeds

GE Announces Completion of BioPharma Sale to Danaher, Receives $20 Billion Net Cash Proceeds

GE Chairman and CEO H. Lawrence Culp, Jr., said, “Completing the sale of BioPharma represents a critical milestone on our multi-year transformation, fortifying our considerable sources to de-risk our balance sheet and continue to solidify our financial position. I am proud of the teams for completing this transaction amidst a great deal of global change. As we go forward, GE retains one of the world’s leading healthcare companies, using our global scale and technical leadership to deliver better outcomes and more capacity to a world striving for Precision Health.”

Under the terms of the transaction agreement, GE received a total consideration of $21.4 billion, including approximately $21 billion in cash as well as Danaher’s assumption of certain pension liabilities. After taking into account deal taxes, deal fees and factored receivable balances, net proceeds to GE totaled approximately $20 billion.

About GE
GE rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company’s dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE’s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE’s mission and deliver for its customers.

Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus

Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus

Covalon Technologies Ltd. , an advanced medical technologies company, announces  its new breakthrough antimicrobial technology formulated to kill the COVID-19 virus (or “SARS-CoV-2”) and other viruses, bacteria, and pathogens.

The new technology, called CovaGuard™, has been specifically formulated to be effective at killing pathogens like the COVID-19 virus on contact with the added benefit of providing persistent protection by trapping and deactivating microbes over an extended period of time. Based on testing to date, the CovaGuard technology has demonstrated sustained activity of up to four days. The CovaGuard technology is designed to be safely applied on skin as well as protective medical equipment like masks and gloves, whether used for the first time or reused.

The Company has filed for a patent on the CovaGuard technology.

Like most sanitizers, CovaGuard adheres to the United States Centers for Disease Control guidelines by utilizing a high concentration of alcohol as its base to provide immediate contact-killing effectiveness within seconds. However, the alcohol quickly evaporates and stops killing microbes. To overcome this, the breakthrough CovaGuard technology is formulated with other ingredients that are intended to continue to remain active and provide sustained protection for days after the alcohol has evaporated. CovaGuard forms an invisible protective film barrier on skin and a wide variety of surfaces, including non-porous materials and fabrics such as medical masks and protective clothing. CovaGuard creates a lasting protective effect using a mixture of compounds that contain active antiviral and antimicrobial agents that work together to trap, deactivate, and kill viruses like the COVID-19 virus, bacteria, and other pathogens.

Brian Pedlar, Covalon’s Chief Executive Officer, said, “With the exponential spread of the novel coronavirus, we immediately created a COVID-19 task force in our highly-regarded lab. Our mission was to create a new technology that could help to reduce the spread of the COVID-19 virus and protect healthcare workers, first responders, patients, and the general public. I am so incredibly proud of the breakthrough they have devised at great personal sacrifice, especially under the trying times we are all facing.”

Dr. Val DiTizio, Covalon’s Chief Scientific Officer, said, “We have leveraged Covalon’s vast experience with infection control, skin integrity, and wound healing, along with our decades of experience killing pathogens, to create a novel technology that we believe is significantly more effective than current solutions on the market today.”

Covalon has identified several initial products that will comply with current regulatory requirements that can be legally marketed in Canada and the United States immediately.

The CovaGuard technology can also enable the rapid formulation of numerous other products that can be developed for:

Medical companies and manufacturers
Hospitals and healthcare providers
Healthcare workers and first responders
Consumers
Consumer packaged goods companies
Pharmacy chains

Versions of the CovaGuard technology can be used to manufacture hand sanitizers, healthcare-personnel hand washes, surgical scrubs, first-aid antiseptics, and medical mask sanitizing sprays that comply with current regulations so they can be immediately introduced to help during the COVID-19 crisis. The CovaGuard technology can also be incorporated into the manufacture of surgical masks and other protective equipment. Other formulations and applications are being investigated by Covalon and in conjunction with other medical and consumer product manufacturers who wish to license CovaGuard for use with their offerings.

While investigating such partnerships with large medical companies and other manufacturers, Covalon will in the interim begin manufacturing a CovaGuard Hand Sanitizer and a CovaGuard Medical Mask Sanitizer Spray designed to be used on a surgical or N95 mask either prior or after first use, if the mask is intended to be reused.

The Company intends to make these products available through various distribution channels and medical partners. Covalon currently works with many other medical companies by leveraging its patented antimicrobial delivery systems and developing antimicrobial products for distribution into the market in the areas of vascular access and surgical and wound care.

Chief Scientific Officer Dr. DiTizio further elaborated, “CovaGuard’s unique antimicrobial formulation has three mechanisms that provide antimicrobial protection. It ensures the rapid killing of bacteria, fungi, and viruses on contact; it maintains persistent antimicrobial protection due to its non-volatile active agents and proprietary delivery system; and it traps pathogens that contact its persistent barrier to increase kill rates and reduce the spread of pathogens. The protective barrier that CovaGuard creates on the skin mimics the natural lipid barriers that are found on skin. The difference is that the CovaGuard barrier also contains antimicrobials that actively kill pathogens, including enveloped viruses like the COVID-19 virus, SARS-CoV-2. The water-repellent nature of the CovaGuard barrier helps prolong its effectiveness, as it won’t be easily removed by exposure to moisture. The CovaGuard active agents have been shown to be very effective against a wide range of microbes, such as Gram-negative and Gram-positive bacteria, fungi, and viruses, especially enveloped viruses like SARS-CoV-2.”

CovaGuard contains a proprietary combination of compounds that includes ethanol, benzalkonium chloride, and other compounds that work together to create a unique persistent barrier film with antiviral and antimicrobial properties. The active ingredients in CovaGuard have a long history of being highly effective against enveloped viruses, including coronaviruses such as SARS-CoV and MERS-CoV, as well as similar influenza viruses including the H1N1 and H5N1 strains. The components of the formulation also have been shown to have potent antimicrobial and antifungal activity against numerous other microbes. Covalon’s in-house testing using surrogate pathogens that mimic the responses of coronaviruses has shown CovaGuard to be highly effective, with sustained activity of up to four days.

The Company intends to continue testing the efficacy of the CovaGuard technology and the resulting products that are intended to be released that are based on the CovaGuard technology.

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon’s technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

FDA authorizes two-minute antibody testing kit to detect coronavirus

FDA authorizes two-minute antibody testing kit to detect coronavirus

BODYSPHERE Inc., announced they are distributing a new Two-Minute Testing Kit for the diagnosis of the novel coronavirus (COVID-19). The U.S. FDA issued Emergency Use Authorization for the test which uses antibodies in blood to test for current or past infection. The tests have a 91% clinical specificity rate and a 99% clinical sensitivity rate. Results are delivered on site in as fast as two minutes. This is a game changer as today in the United States, most COVID-19 testing results take between two to seven days.

The COVID-19 IgG/IgM Rapid Test Cassette is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG and IgM) for the Novel coronavirus in human whole blood/serum/plasma. The test can be administered as easy as a glucose test but is designed strictly for use by medical professionals.

“When we realized we had the ability to step up and fight this pandemic at a critical point, we focused all our resources on bringing the rapid test kits, masks and other critical supplies to the front lines as soon as possible.” said Charlton E. Lui, Chief Executive Officer of BODYSPHERE. Lui continued, “Thankfully, when our perpetual quest for improving health put us in a position to deliver this lifesaving product – it became quite clear what we had to do.”

The test kits have been used successfully in several states where large roll outs are planned to combat the spread of the virus. BODYSPHERE is working closely with federal agencies and states to quickly deploy test kits across the country to hospitals, urgent care and emergency rooms. The company has already contracted cargo planes to deliver the product to the front lines faster. BODYSPHERE is positioned to have millions of test kits on the front lines in weeks.

Lui added, “At BODYSPHERE, we understand and have built an infrastructure to tackle some of the most daunting issues the world has faced; be it climate change, our ecosystem, pollution, public health concerns and the opioid crisis.”

ABOUT BODYSPHERE:

FEED YOUR BODY. FEED YOUR HEAD. FEED YOUR SOUL.

BodySphere provides health alternatives to pain and treatment medications, supplements, carbon positive solutions, military and consumer protective gear, CO2 sequestration building materials, BODYSPHERE wear and clothing. From our retail pharmacies, private-label program to our online sales channels and our prescription products to our natural therapies, BodySphere delivers powerful quality solutions. We are committed to educate, train, employ, produce solutions, products and fund research and development that have a positive and everlasting effect for the future of humanity. Visit us at www.mybodysphere.com

ABOUT CHARLTON LUI:

Charlton Lui is an established technological leader with a notable resume that includes tenure at the beginnings of Apple Computers, acquisitions for IBM and Microsoft, and Stanford Research Institute. Mr. Lui holds over 40 patents and worked with Bill Gates to develop the Tablet PC. He’s also responsible for co-founding Truetype font and the first Multi-media Internet conferencing. Charlton Lui has been featured in worldwide publications such as the Times, the cover of the Financial Times, USA Today, The Chicago Tribune and more.

The Two-Minute Test Kit has not been FDA cleared or approved. It has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories and patient care settings.

Medline to reprocess N95 respirators to fight COVID-19 spread

Medline to reprocess N95 respirators to fight COVID-19 spread

Medline Industries has agreed to reprocess 100,000 N95 respirators and other face masks per day in its facilities beginning as early as this week.

The process that Medline plans to use is close to receiving FDA emergency use approval (EUA) and will supplement the more than 38 million masks the company has distributed on average each month in 2020, according to Northfield, Ill.-based Medline.

Medline CEO Charlie Mills agreed to the deal during a White House supply chain roundtable on Sunday. Last week, the company reopened the medtech sterilization section of its Waukegan, Ill. plant after investing $10 million in upgrades to control emissions of the carcinogenic sterilant gas ethylene oxide. Privately owned Medline voluntarily halted sterilization at the Waukegan plant in January to perform the upgrades in order to comply with a state EtO emission-control law that went into effect in 2019.

“The healthcare systems of America are doing heroes’ work right now, and Medline will do all that we can to help them take care of patients and themselves through the pandemic,” Mills said in a news release. “Whether it’s converting manufacturing capabilities to produce hand sanitizer or developing a creative way to renew face masks, we are pursuing every opportunity to make a difference.”

The company already has distributed 15 million more masks to healthcare providers so far this year than in the first quarter of 2019, and its trucks are making thousands of deliveries per day to healthcare providers across the country, Medline said.

This month, Medline began air-freighting personal protective equipment (PPE) to the U.S. to cut three to four weeks out of the typical supply chain cycle. Medline also doubled its production of reusable face masks and surgical gowns to supplement PPE supplies.

“We realize our critical role in healthcare, and I can speak for every employee of Medline when I say our top priority is to get more PPE and other medical supplies into the hospitals, nursing homes and physician offices caring for patients.” Mills said. “This is an unprecedented time, and we won’t stop until we’ve done everything we can to help defeat COVID-19.”

Mercedes F1 engineers help make a breathing aid for coronavirus patients in less than 100 hours

Formula One engine manufacturer Mercedes has teamed up with clinicians and university engineers in London to design a breathing aid for coronavirus patients that can be quickly mass produced, a development that could help reduce the need for ventilators.

The Continuous Positive Airway Pressure (CPAP) device, which was re-engineered from an existing machine in fewer than 100 hours, has been recommended for use by the UK Medicines and Healthcare products Regulatory Agency, according to a statement from University College London (UCL), which worked on the project.

CPAP devices have been used in hospitals in China and Italy to treat coronavirus infections, with reports indicating that roughly half of such patients have avoided the need for ventilators, according to the statement. There is a severe shortage of ventilators in many countries, including Britain, that are fighting severe outbreaks.

“These devices will help to save lives by ensuring that ventilators, a limited resource, are used only for the most severely ill,” said professor Mervyn Singer, a critical care consultant at University College London Hospitals (UCLH).

CPAP machines help to keep patients’ airways open and increase the amount of oxygen entering the lungs by pushing air and oxygen into the mouth and nose at a continuous rate. According to the statement, 100 of the newly-designed machines will be used in clinical trials at UCLH, with “rapid rollout to hospitals around the country ahead of the predicted surge in Covid-19 hospital admissions.”

Professor Tim Baker of UCL said a process that can take years had been reduced to a matter of days, explaining that the team had worked “all hours” to disassemble and analyze an existing device before using computer simulations to “create a state-of-the-art version suited to mass production.”
Following clinical trials, Mercedes and other F1 teams could produce up to 1,000 of the devices per day.

Some experts have raised concerns that using CPAP machines may put hospital workers at risk by creating a mist of droplets containing the virus. But Britain’s National Health Service has recommended the devices be used to treat coronavirus patients, saying the risk of infection is low so long as staff wear personal protective equipment.

Andy Cowell, managing director of Mercedes-AMG High Performance Powertrains, said he was proud that the F1 engine maker was able to participate and help deliver the device on the “fastest possible timeframe.”

Lewis Hamilton won his sixth F1 world title in 2019 driving a Mercedes car. The start of this year’s season has been postponed at least until June because of the pandemic.

Race to a ventilator
Separately, a consortium of businesses including Airbus (EADSF), Ford (F) and BAE Systems (BAESF) and several F1 teams said Monday that it received orders from the British government to produce over 10,000 ventilators.

The consortium said it would start production this week, and that it expects to receive prompt regulatory approval following a final audit. F1 teams working on the project include McLaren, Mercedes, Red Bull Racing, Renault Sport Racing and Williams.

Last week, vacuum cleaner maker Dyson said it had designed a new ventilator to treat coronavirus patients. It plans to make 10,000 of the devices for the UK government and donate 5,000 to the global effort.

DYNALABS joins forces with Mayo Clinic to help hospitals prevent medication diversion

DYNALABS joins forces with Mayo Clinic to help hospitals prevent medication diversion

DYNALABS and Mayo Clinic have joined forces to launch ANiGENT, a new company whose proprietary software uses machine learning to deliver a state-of-the-art drug diversion surveillance system. The novel platform will help hospitals and health systems reduce patient and worker harm from potential drug diversion and prevent regulatory or legal risk. The collaboration unites the clinical expertise of Mayo Clinic with analytic lab testing company DYNALABS, which offers an industry-leading technology.

Headquartered in St. Louis, Mo., ANiGENT will be led by V.C. Jun Fabella Jr., chief executive officer and managing partner, and Charles D’Amato, chief product officer and managing partner. Previously, Fabella was president of DYNALABS and D’Amato served as pharmacist and supervisor of the drug diversion prevention program for Mayo Clinic Hospital in Phoenix, Ariz.

“The current environment we’re experiencing increases the need for a drug diversion solution now more than ever,” said Fabella. “The anticipated influx of patients with significant health issues will test the ability of our health systems to monitor and track appropriate drug use. Many will come up short, leading to serious patient risks and regulatory fines because they don’t have adequate controls in place to prevent these occurrences.”

“There is a rising demand to improve protocols for preventing drug diversion,” added D’Amato. “Organizations are seeking out new technology that can solve these problems, and until recently, there was no such solution.” “The active, predictive analytic system is an effective tool for continuous quality improvement that allows health systems to identify potential problems indicative of drug diversion and distinguish between wrong doing and human error,” said Mark H. Siska, RPh, chief pharmacy informatics officer at Mayo Clinic.

ANiGENT will deliver a comprehensive software solution that enables healthcare organizations to track and monitor all users and drugs at any location to prevent occurrences of drug diversion. The patent-pending software is based on the Medication Administration & Analysis Program (MAAP), a solution that Mayo Clinic has used at its own facilities. MAAP will leverage machine-learning algorithms to:

Continually capture and analyze data
Rapidly identify and prevent drug diversion
Pinpoint areas that need process improvement

An additional value MAAP offers is its ability to recapture lost revenues by improving the charge capture process.

“While MAAP was initially designed to reduce a health facility’s risk of drug diversion, the software platform also corrected procedural gaps, lowering costs and improving revenue streams,” said Fabella.

ANiGENT’s first customer will be Mayo Clinic as the health system continues to integrate MAAP across its facilities.

ABOUT ANiGENT
ANiGENT is the first and only software provider to deliver a comprehensive solution that helps facilities track and monitor all users and all drugs in all locations. The company is a collaboration between Mayo Clinic and DYNALABS. ANiGENT delivers a comprehensive, patent-pending solution based on Medication Administration & Analysis Program (MAAP).

Thyrocare – India’s 1st private lab approved by ICMR for COVID – 19 Test

Thyrocare – India’s 1st private lab approved by ICMR for COVID – 19 Test

Focusing on preventive health care, Thyrocare becomes the first Indian diagnostic private laboratory to provide COVID testing in Mumbai. In the initial phase, Thyrocare has started the test in Mumbai. Once Lock Down is lifted, we will make our services available for metros and other cities too.

Though we are serving at the door steps of patients in city of Mumbai, we are more keen to explore the BtoB model by partnering with local hospitals in Mumbai, Navi Mumbai, Thane, Pune and Nashik.

Dr. A. Velumani, Chairman and Managing Director of Thyrocare Technologies Ltd said, “ Thyrocare wishes to keep it affordable, reach to the bottom of the pyramid and produce significant impact in the nation’s fight against #COVID. Partnering with local hospitals is the best way to disseminate this solution countrywide”

Some of the key points to notice.

1. COVID testing as now available only in Mumbai, Navi Mumbai and Thane.
2. From 1 April 2020 it would be in Pune and Nashik.
3. Once Lock Down is lifted it would be available in all air connected cities
4. Sample is Throat or Nasal Swab and not Blood.
5. It is priced as of now at Rs.4500 and it would go down after Lockdown
6. Swab collection needs training and care and personnel are trained for home service
7. It takes 6 hours to report once the sample reaches the laboratory.
8. Dedicated mail ID for is covid@thyrocare.com and WhatsApp Number : 9321414230

About Thyrocare

Thyrocare is a BSE and NSE listed entity with presence in 3000 locations including 10 countries and is focused on Preventive care in Lifestyle disorders.

With a belief that ‘Quality’ is the heart of any intelligent management, Thyrocare became one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditation like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008 and CAP (College of American Pathologists) certification in 2007.

Cobham Advanced Electronic Solutions Space Pedigree Aids in Coronavirus Fight

Cobham Advanced Electronic Solutions Space Pedigree Aids in Coronavirus Fight

Cobham Advanced Electronic Solutions (CAES), a leading provider of mission critical electronic solutions, announced accelerated demand for its technology to be used for rapid sequencing of coronavirus samples for analysis and to aid in diagnosing and treating coronavirus patients.

Cobham Advanced Electronic Solutions’ Application Specific Integrated Circuits (ASIC) are used in advanced devices used to deliver the genomic sequence of the SARS-CoV-2 virus that causes the COVID-19 disease, enabling insights into how the virus is transmitted and how it evolves. CAES ASICs are also a key technology used by a leading global provider of computed tomography (CT) scanners used to help diagnose respiratory conditions. Cobham has recently seen an increase of approximately 30 percent in demand for its medical ASIC products.

Cobham Advanced Electronic Solutions ASICs”Developing and producing high performing electronic solutions that work the first time, every time under challenging conditions is in our DNA,” said Shawn Black, CEO, Cobham Advanced Electronic Solutions. “We entered the medical market twenty years ago, employing the same advanced engineering, development, and manufacturing expertise that we developed in the space industry.

Working closely with our customers, we were able to balance their high-performance needs with cost efficiency. Today, we are proud that our ASIC solutions are able to contribute to the world’s fight against the coronavirus.” Leveraging an unparalleled space pedigree, particularly in radiation hardness and high reliability, Cobham Advanced Electronic Solutions has developed innovative digital and mixed-signal ASICs that perform in the harshest environments, including medical radiology.

With an extensive portfolio of intellectual property and design libraries as well as on-site design, packaging, testing, and reliability analysis, Cobham Advanced Electronic Solutions ASICs provide customers with world-class performance, the highest levels of reliability and very long-term availability.

About Cobham Advanced Electronic Solutions Cobham Advanced Electronic Solutions (CAES) provides a number of mission-critical and specialized solutions for harsh environments. Cobham Advanced Electronic Solutions supplies defense, space, commercial aviation, security, medical, and industrial markets with critical solutions for communication on land, at sea, and in the air and space, by moving data through off-the-shelf and customized products and subsystems including RF, microwave, and high reliability microelectronics, antenna apertures and motion control solutions. www.cobhamaes.com

FDA Approves Next-Generation ZOLL TherOx System for Widowmaker Heart Attack Patients

FDA Approves Next-Generation ZOLL TherOx System for Widowmaker Heart Attack Patients

ZOLL Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced it has received U.S. FDA approval of the second-generation TherOx System, which provides SuperSaturated Oxygen (SSO2) Therapy and reduces heart muscle damage in “widowmaker” heart attack patients.

“The TherOx SSO2 Therapy system is another example of ZOLL’s commitment to technology that provides advanced clinical performance to improve outcomes,” said Neil Johnston, President, ZOLL Circulation. “We are pleased to provide the interventional cardiologist with a new treatment that augments the standard of care for patients.”

SSO2 Therapy delivers hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularization via angioplasty and stenting of the blocked coronary artery. It is indicated for patients who suffer the most serious kind of heart attack — left anterior descending ST-elevation myocardial infarction (LAD STEMI), also known as a “widowmaker” due to the high mortality rate — and who are treated within six hours

of symptom onset. SSO2 Therapy is the first and only FDA-approved treatment beyond percutaneous coronary intervention (PCI) to reduce muscle damage in heart attack patients.2 “SSO2 Therapy is the only point-of-care treatment for LAD STEMI patients which results in a predictable reduction in infarct size and improved left ventricular function1,5” said Richard A. Schatz, MD, Research Director, Cardiovascular Interventions, at Scripps Memorial Hospital in La Jolla, CA.

“This can translate to heart failure prevention and patient survival.” Historically, angioplasty and stenting have been the standard of care in treating heart attacks. Many patients do not achieve maximum clinical benefit and suffer from reduced heart function. More than 30% of severe heart attack patients develop heart failure,3 and of those, 50% will die within five years.3 SSO2 Therapy has been shown in prospective clinical trials to safely reduce infarct size in “widowmaker” heart attack patients.5 Decades of research on heart attack patients has demonstrated that infarct size reduction is correlated with reduced mortality and heart failure, and better left ventricular function

About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, treat victims needing resuscitation and acute critical care.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corporation, with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

MedSign announces the launch of Qortex to help fight against COVID-19

MedSign announces the launch of Qortex to help fight against COVID-19

MedSign International Corporation, a leading-edge Telehealth company, announces the nationwide launch of Qortex™;the first and onlyhomeTV-based Telehealth solution that enables doctors, hospitals, nurses, and home care agencies  to deliver virtual medical services to patients confined to their homes,especially during thisCOVID-19 pandemic.

“With the current stay-at-home mandate, Qortex can help alleviate the fear and anxiety created by isolation andoffers peace of mind by allowing even the most technology averse seniors to have real-time, full screen, face- to-face visits with their care providers and loved ones, using what they know best… their own TV.”said Tom Conroy, MedSign CEO and Inventor of Qortex. “I originally created Qortex to keep my family healthy, safe and secure, including my 92 year-old Dad who served in World War II, ” states Conroy.

“Now Irealize Qortex’s capabilities can help everyone who is sick at home or recovering from hospitalization, as well as those individuals now affected by the Coronavirus. As aretired Air Force officer, I also knowQortex can play a vital role to aidfellow Veterans who have chronic illnesses and are remote, disabled, depressed or suicidal, by providing them immediate access to virtual care and counseling 24/7 in the comfort of their home, through their TV screen.With Qortex, they’re never alone.” Conroy added.

The patent pending Qortex System consists of a communication hub, high-def camera and specially designed senior simple remote control, that’s easy to install.The system connects with any Internet service and HDMI television, and is compatible with all smartphones and tablets. Qortex offers a single comprehensive platform to support all Telehealth needs, including scheduling and on-screen reminders for medication,hydration and therapies.

It also incorporates a suite of health, wellness and security apps including an advanced Personal Emergency Response System (PERS).The Qortex system is currently used byhome care agencies in Florida and Southern California,and will soon be available through hospitals, physician groups, home care companies, professional healthcare organizations,and government agencies, who are on the front line of defense for our country during this national emergency.

1...634635636...1,125Page 635 of 1,125

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »